Production (Stage)
Compass Therapeutics, Inc.
CMPX
$2.37
-$0.045-1.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 51.23% | 19.18% | 17.19% | 51.61% | 5.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.69% | 7.67% | 2.62% | 19.18% | 31.50% |
| Operating Income | -40.69% | -7.67% | -2.62% | -12.81% | -31.50% |
| Income Before Tax | -54.19% | -12.06% | -5.19% | -15.94% | -37.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.19% | -12.06% | -5.19% | -15.94% | -37.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.19% | -12.06% | -5.19% | -15.94% | -37.64% |
| EBIT | -40.69% | -7.67% | -2.62% | -12.81% | -31.50% |
| EBITDA | -41.30% | -7.89% | -2.84% | -13.19% | -32.56% |
| EPS Basic | -52.28% | 0.00% | 2.56% | -6.74% | -27.42% |
| Normalized Basic EPS | -52.23% | 0.00% | 2.66% | -6.83% | -27.32% |
| EPS Diluted | -52.28% | 0.00% | 2.56% | -6.74% | -27.42% |
| Normalized Diluted EPS | -52.23% | 0.00% | 2.66% | -6.83% | -27.32% |
| Average Basic Shares Outstanding | 1.19% | 12.03% | 7.98% | 8.57% | 8.10% |
| Average Diluted Shares Outstanding | 1.19% | 12.03% | 7.98% | 8.57% | 8.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |